(Q46921350)

26 December 2017

title

Everolimus treatment of refractory epilepsy in tuberous sclerosis complex (English)

1 reference

26 December 2017

1 reference

Darcy A Krueger

1

1 reference

26 December 2017

Angus A Wilfong

2

1 reference

26 December 2017

Katherine Holland-Bouley

3

1 reference

26 December 2017

Anne E Anderson

4

1 reference

26 December 2017

Karen Agricola

5

1 reference

26 December 2017

Cindy Tudor

6

1 reference

26 December 2017

Maxwell Mays

7

1 reference

26 December 2017

Christina M Lopez

8

1 reference

26 December 2017

Mi-Ok Kim

9

1 reference

26 December 2017

David Neal Franz

10

1 reference

26 December 2017

publication date

10 September 2013

1 reference

26 December 2017

published in

Annals of Neurology

1 reference

26 December 2017

volume

74

1 reference

26 December 2017

issue

5

1 reference

26 December 2017

page(s)

679-687

1 reference

26 December 2017

Prevalence of tuberous sclerosis in UK.

cites work

1 reference

Current management of tuberous sclerosis complex

21 January 2018

1 reference

Tuberous sclerosis complex: a review of neurological aspects

21 January 2018

1 reference

Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges.

21 January 2018

1 reference

The tuberous sclerosis complex

21 January 2018

1 reference

The TSC1-TSC2 complex: a molecular switchboard controlling cell growth

21 January 2018

1 reference

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

21 January 2018

1 reference

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

21 January 2018

1 reference

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

21 January 2018

1 reference

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

21 January 2018

1 reference

Efficacy and safety of sirolimus in lymphangioleiomyomatosis

21 January 2018

1 reference

Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function

21 January 2018

1 reference

A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival

21 January 2018

1 reference

Rapamycin reduces seizure frequency in tuberous sclerosis complex

21 January 2018

1 reference

The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy

21 January 2018

1 reference

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

21 January 2018

1 reference

Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria

21 January 2018

1 reference

The Nisonger Child Behavior Rating Form: typical IQ version

21 January 2018

1 reference

The Nisonger CBRF: a child behavior rating form for children with developmental disabilities

21 January 2018

1 reference

Recent advances in neurobiology of Tuberous Sclerosis Complex.

21 January 2018

1 reference

Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies

21 January 2018

1 reference

Developing Antiepileptogenic Drugs for Acquired Epilepsy: Targeting the Mammalian Target of Rapamycin (mTOR) Pathway

21 January 2018

1 reference

Everolimus alters white matter diffusion in tuberous sclerosis complex.

21 January 2018

1 reference

Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma

21 January 2018

1 reference

Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex.

21 January 2018

1 reference

Nursing implications for the lifelong management of tuberous sclerosis complex

21 January 2018

1 reference

Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex

21 January 2018

1 reference

Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.

21 January 2018

1 reference

Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis

21 January 2018

1 reference

Rapamycin attenuates aggressive behavior in a rat model of pilocarpine-induced epilepsy

21 January 2018

1 reference

Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder

21 January 2018

1 reference

Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy

21 January 2018

1 reference

mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo

21 January 2018

1 reference

Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice

21 January 2018

1 reference

De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly

21 January 2018

1 reference

Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia.

21 January 2018

1 reference

Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia

21 January 2018

1 reference

Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury

21 January 2018

1 reference

Mapping the spatio-temporal pattern of the mammalian target of rapamycin (mTOR) activation in temporal lobe epilepsy

21 January 2018

1 reference

mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ANA.23960

1 reference

26 December 2017

PubMed ID

23798472

1 reference

26 December 2017